1. Scrip
  2. >>Archive

Astex's 'unique' ops to remain intact after Otsuka acquisition

 
• By Ian Haydock

The number of cases where small drug discovery firms have been stripped back to their core assets following a Big Pharma acquisition are too numerous to count, but all the indications are that Otsuka plans to keep the operations and staff of intended new group member Astex Pharmaceuticals intact.

The number of cases where small drug discovery firms have been stripped back to their core assets following a Big Pharma acquisition are too numerous to count, but all the indications are that Otsuka plans to keep the operations and staff of intended new group member Astex Pharmaceuticals intact.

The Japanese giant announced on 5 September that it would launch a cash merger and tender offer to buy the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.